The drugmaker’s U.S. plans comes on the heels of a rough quarter, with lower vaccine demand driving down Q3 sales by 15% year ...

GlaxoSmithKline (GSK) has agreed to acquire Chimagen Biosciences’ CMG1A46, a clinical-stage therapy designed to target B cell ...

GSK CEO Emma Walmsley said the sector would need to wait to see who is appointed in key roles in the Trump administration to ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily ...

Shares of GSK PLC GSK dropped 1.59% to £13.92 Tuesday ... Supported by world-class markets data from Dow Jones and FactSet, ...

By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Bernstein analyst Justin Smith maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

This writer thinks GSK shares appear very cheap after the Q3 results, making him wonder if now's the time for him to invest ...

BRENTFORD, Britain — BRENTFORD, Britain — GSK plc (GSK) on Wednesday reported a loss of $75.4 million in its third quarter. The Brentford, Britain-based company said it had a loss of 4 cents per share ...

GSK has reported pre-tax profit in the fourth ... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.

Luxury fashion and lifestyle group Kering, pharma giant GSK and building materials producer Holcim have become the first ...

GlaxoSmithKline is under pressure from shareholders ... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.